Illume Bio

Intelligence, evolved.

We are building AI models to predict how molecular changes affect binding and biological activity. That understanding guides the evolution of new drugs.

A better binder
is only the beginning.

Strong binding alone does not make a useful drug. Our AI models are being developed to connect molecular edits to affinity, specificity, stability and biological response.

Three molecular strands with a compact gold ring, a fused coral double ring and a branched green group at the same sequence position.

Change one position.

Explore different shapes and chemical groups at one position. Study what each change does.

Find the right fit.

Use shape, chemistry and physical forces to understand how a candidate fits and binds.

Design for the response.

Aim to block a harmful interaction while preserving the proteins and functions the body needs.

Nature’s search strategy.
With a therapeutic purpose.

Our approach combines AI models, molecular physics and computational directed evolution. Our drug candidates are varied, evaluated and selected over successive generations.

Every target calls for different selection pressures. We are training AI models on the relationship between a candidate’s shape and chemistry, its target binding site, and experimentally measured binding affinity. That understanding guides which changes to explore and which experiments come next.

Start with a target protein and the biological effect the drug needs to produce. Choose a binding site to explore.

Generation 01

Founders

Supported by

  • FR8
  • Emergent
    Ventures
  • 3FVC
  • MIT Club
    of Singapore
  • Tiger Launch

Thousands of targets.
A different solution for each.

Illume Bio is a drug discovery company building AI models for the scale of that challenge. Our ambition is to extend drug design to targets with limited binding data, using what we learn across programs to guide new candidates and the experiments that test them.